JP2011530537A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530537A5
JP2011530537A5 JP2011522303A JP2011522303A JP2011530537A5 JP 2011530537 A5 JP2011530537 A5 JP 2011530537A5 JP 2011522303 A JP2011522303 A JP 2011522303A JP 2011522303 A JP2011522303 A JP 2011522303A JP 2011530537 A5 JP2011530537 A5 JP 2011530537A5
Authority
JP
Japan
Prior art keywords
sequence
cap03
another embodiment
dna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011522303A
Other languages
English (en)
Japanese (ja)
Other versions
JP5583667B2 (ja
JP2011530537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053264 external-priority patent/WO2010017544A2/en
Publication of JP2011530537A publication Critical patent/JP2011530537A/ja
Publication of JP2011530537A5 publication Critical patent/JP2011530537A5/ja
Application granted granted Critical
Publication of JP5583667B2 publication Critical patent/JP5583667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011522303A 2008-08-08 2009-08-10 長時間作用型ｄｎａデンドリマーおよびその方法 Active JP5583667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18831808P 2008-08-08 2008-08-08
US61/188,318 2008-08-08
PCT/US2009/053264 WO2010017544A2 (en) 2008-08-08 2009-08-10 Long-acting dna dendrimers and methods thereof

Publications (3)

Publication Number Publication Date
JP2011530537A JP2011530537A (ja) 2011-12-22
JP2011530537A5 true JP2011530537A5 (https=) 2012-03-15
JP5583667B2 JP5583667B2 (ja) 2014-09-03

Family

ID=41664237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522303A Active JP5583667B2 (ja) 2008-08-08 2009-08-10 長時間作用型ｄｎａデンドリマーおよびその方法

Country Status (7)

Country Link
US (1) US20120122800A1 (https=)
EP (2) EP2657342B1 (https=)
JP (1) JP5583667B2 (https=)
AU (1) AU2009279458B2 (https=)
CA (1) CA2731521C (https=)
IL (1) IL210841A (https=)
WO (1) WO2010017544A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US20140228234A1 (en) 2011-06-15 2014-08-14 Naomi B. Zak Target-recognition compositions comprising novel synthetic conjugates for trapping and diagnosis of a target molecule
CN103957997B (zh) * 2011-10-25 2018-09-21 奥麒个人护理产品公司 含有顺序发酵或同时发酵的提取物的组合物
US9651549B2 (en) * 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
JP2016513089A (ja) * 2013-02-01 2016-05-12 ジェニスフィア・エルエルシー 細胞への遺伝子送達のための機能性ｄｎａデンドリマー
WO2014153394A1 (en) 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
CN107530439B (zh) * 2015-04-17 2021-06-18 詹尼斯费尔公司 用于治疗癌症的对人抗原R表达的siRNA抑制
WO2017143171A1 (en) * 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
IL260983B (en) * 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
EP3759225A1 (en) 2018-03-02 2021-01-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
JP7082659B2 (ja) * 2018-05-11 2022-06-08 中国塗料株式会社 防汚塗料組成物、防汚塗膜、防汚塗膜付き基材及び防汚方法
EP4022058A2 (en) 2019-08-30 2022-07-06 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
PH12021553295A1 (en) * 2019-12-23 2022-08-01 Illumina Cambridge Ltd Nanoparticle with single site for template polynucleotide attachment
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
WO2021220053A2 (en) 2020-04-27 2021-11-04 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
KR20230035237A (ko) 2020-05-12 2023-03-13 일루미나, 인코포레이티드 재조합 말단 데옥시뉴클레오티딜 트랜스퍼라제를 사용하여 변형된 염기를 갖는 핵산의 생성
MX2023004104A (es) * 2020-10-09 2023-06-29 Sumitomo Pharma Co Ltd Conjugado de acido oligonucleico.
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
EP4703381A1 (en) 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antibodies against icam-1 and applications thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5175270A (en) 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6117631A (en) 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
EP1005573B1 (en) 1997-07-29 2006-05-24 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
EP1530581A4 (en) * 2002-06-12 2006-08-30 Datascope Investment Corp POLYMERIC MARKING MOLECULES
US7223544B2 (en) * 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Similar Documents

Publication Publication Date Title
JP2011530537A5 (https=)
MX2025014047A (es) Composiciones para usarse en el tratamiento de atrofia muscular y distrofia miotonica
JP2015518721A5 (https=)
JP2013510561A5 (https=)
JP2014509511A5 (https=)
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2011133886A3 (en) Production of heteromultimeric proteins
JP2012531889A5 (https=)
JP2013516190A5 (https=)
JP2011529686A5 (https=)
JP2009514877A5 (https=)
JP2010273685A5 (https=)
CN113330117A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2017093448A5 (https=)
WO2008092081A8 (en) Targeted delivery of sirna
JP2012505657A5 (https=)
WO2008036406A3 (en) Compositions and methods related to protein displacement therapy for myotonic distrophy
JP2010529860A5 (https=)
JP2006525796A5 (https=)
WO2010077422A3 (en) Formulations of single domain antigen binding molecules
JP2009516517A5 (https=)
JP2018530530A5 (https=)
JP2012504416A5 (https=)
WO2007127219A3 (en) Targeted delivery to leukocytes using protein carriers
MX2015005352A (es) Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas.